Notice2021-12179
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 10, 2021
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 110 (Thursday, June 10, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 110 (Thursday, June 10, 2021)]
[Notices]
[Pages 30967-30968]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-12179]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Benjamin Hurley at 240-669-5092;
<a href="/cdn-cgi/l/email-protection#3456515a5e55595d5a1a5c414658514d745a5d5c1a535b42"><span class="__cf_email__" data-cfemail="0260676c68636f6b6c2c6a77706e677b426c6b6a2c656d74">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Producing Modified Vaccinia Ankara (MVA) Virus With Continuous Cell
Lines: Modifications of Mammalian Host Cells for Increasing MVA Vaccine
Production Yield
Description of Technology: Modified vaccinia Ankara (MVA) is a
well-known and important platform for vaccine development, and many
MVA-based vaccine trials are currently underway to prevent a variety of
microbial diseases. While MVA shows promise as a vaccine platform,
wide-scale industry use of MVA may be currently held back due to MVA's
severe host-restriction, and the fact that large bulks of culture cells
are presently required to produce enough product for mass commercial
use. At present, the range of commonly-used culture cells that can
support high-titer production of MVA is limited to chick embryo
fibroblast (CEF) cells. Unfortunately, the production of CEF cells in
bulk involves many slow and inefficient manufacturing steps both
upstream and downstream. Therefore, especially in the context of
pandemic preparedness, continuous cell lines that allow for efficient,
large-scale MVA propagation would be beneficial.
There is a clear need for an expanded range of cell lines that are
easily maintained in culture, and that allow for the production of high
titers of infectious MVA virus. The present invention provides methods
of modifying non-permissive cell lines in a way that allows for
production of MVA.
Scientists at NIAID have made a breakthrough discovery by
identifying the mammalian Zinc finger antiviral protein (ZAP) as a
restriction factor that inhibits MVA growth in mammalian cells. They
have demonstrated that ZAP abrogation enhanced replication of the MVA
in a range of mammalian cells that are normally non-permissive for MVA
replication. In particular, CRISPR/Cas9 inactivation of ZAP was shown
to produce stable cell lines capable of supporting MVA replication.
Additionally, recombinant host cells engineered to produce vaccinia
virus proteins C12L and C16L have been shown to overcome the host range
inhibition of the MVA.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Vaccine Development: Recombinant continuous cell lines
useful for efficient, large-scale production of MVA.
<bullet> May offer improved vaccine production scaling-response
times, enhancing epidemic/pandemic preparedness.
Competitive Advantages:
<bullet> Overcomes inefficiencies associated with CEF production of
MVA-based vaccines.
Inventors: Bernard Moss, Linda Wyatt, Chen Peng, Gilad Sivan, Shira
Glushakow-Smith, all of NIAID.
Publications:
Liu R, Mendez-Rios JD, Peng C, et al. SPI-1 is a missing host-range
factor required for replication of the attenuated modified vaccinia
Ankara (MVA) vaccine vector in human cells.; PLoS Pathog. 2019.
Peng C, Moss B. Repair of a previously uncharacterized second host-
range gene contributes to full replication of modified vaccinia
virus Ankara (MVA) in human cells. Proc Natl Acad Sci U S A. 2020.
Peng, C, Wyatt, L, Glushakow-Smith, SG, Lal-
[[Page 30968]]
Nag, M, Weisberg, AS, and Moss, B. Zinc-finger antiviral protein
(ZAP) is a restriction factor for replication of modified vaccinia
virus Ankara (MVA) in human cells. PLoS Pathog. 2020, accepted for
publication.
Intellectual Property: HHS Reference No. E-076-2019; International
Application No. PCT/US20/33788.
Licensing Contact: To license this technology, please contact
Benjamin Hurley at 240-669-5092 or <a href="/cdn-cgi/l/email-protection#87e5e2e9ede6eaeee9a9eff2f5ebe2fec7e9eeefa9e0e8f1"><span class="__cf_email__" data-cfemail="ec8e8982868d818582c284999e808995ac828584c28b839a">[email protected]</span></a>, and
reference E-076-2019.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this invention. For collaboration
opportunities, please contact Benjamin Hurley; 240-669-5092,
<a href="/cdn-cgi/l/email-protection#066463686c676b6f68286e73746a637f46686f6e28616970"><span class="__cf_email__" data-cfemail="4527202b2f24282c2b6b2d303729203c052b2c2d6b222a33">[email protected]</span></a>.
Dated: June 2, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-12179 Filed 6-9-21; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 10, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.